Literature DB >> 9044140

Pulmonary function is compromised in children with mediastinal lymphoma.

D R King1, L E Patrick, M E Ginn-Pease, K S McCoy, K Klopfenstein.   

Abstract

PURPOSE: Lymphomas account for nearly 20% of the malignancies in childhood and the majority of patients with Hodgkin's Disease (HD) and non-Hodgkin's lymphoma (NHL) have radiological evidence of mediastinal involvement at presentation. Children with mediastinal tumors are at risk for the development of lethal airway obstruction during general anesthesia. This study quantitates the degree of the airway obstruction and the functional significance of tracheal compression in a cohort of 51 children with HD and NHL.
RESULTS: Thirty patients with HD (mean age, 14.6 years) and 21 with NHL (mean age, 9.2 years) were included in this study. Twenty-five children (49%) had respiratory symptoms at the time of presentation. Respiratory complaints were much more common in children with NHL (76%) when compared with those with HD (30%). Pulmonary function was also significantly worse in the NHL patients who had a mean upright forced vital capacity (FVC) of 66 +/- 21%. The comparable value for the children with HD was 85 +/- 15% (P = .031). Patients with respiratory symptoms at presentation had both obstructive and restrictive deficits of pulmonary function. Their mean upright forced expiratory volume in 1 second (FEV1) was 69 +/- 22% and the FVC was 69 +/- 18%. Children with large mediastinal masses also had significantly decreased pulmonary function compared with those with small tumors. The upright FEV1 for these two groups was 72 +/- 18% versus 98 +/- 15% (P = .016). Their FVC values were 68 +/- 20% and 91 +/- 17%, respectively (P = .049). Mean tracheal compression was measured at 44% in the children with large tumors versus 27% for those with small lesions (P = .048).
CONCLUSION: Children with mediastinal lymphomas have both obstructive and restrictive deficits on pulmonary function testing. Pulmonary function is significantly decreased in patients with NHL, children who present with respiratory symptoms, and those with very large mediastinal masses (mediastinal mass ratio > 45%). The extent of tracheal compression correlates with the size of the mediastinal mass.

Entities:  

Mesh:

Year:  1997        PMID: 9044140     DOI: 10.1016/s0022-3468(97)90197-4

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

1.  Dexmedetomidine for anesthetic management of anterior mediastinal mass.

Authors:  Basem Abdelmalak; Nicholas Marcanthony; Joseph Abdelmalak; Michael S Machuzak; Thomas R Gildea; D John Doyle
Journal:  J Anesth       Date:  2010-05-08       Impact factor: 2.078

Review 2.  Pediatric lymphomas and histiocytic disorders of childhood.

Authors:  Carl E Allen; Kara M Kelly; Catherine M Bollard
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

3.  Selection of appropriate size endotracheal tube in cases of large goiters causing tracheal compression.

Authors:  Cherish Paul; Souvik Chaudhuri; Tim Thomas Joseph
Journal:  Anesth Essays Res       Date:  2012 Jul-Dec

4.  Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses.

Authors:  Doralina L Anghelescu; Laura L Burgoyne; Tiebin Liu; Chin-Shang Li; Ching-Hon Pui; Melissa M Hudson; Wayne L Furman; John T Sandlund
Journal:  Paediatr Anaesth       Date:  2007-11       Impact factor: 2.556

5.  Diagnosis of anterior mediastinal mass lesions using the Chamberlain procedure in children.

Authors:  Sonia Salas Valverde; Yessica Gamboa; Sergio Vega; Max Barrantes; Mario Gonzalez; Jose Barrantes Zamora
Journal:  Pediatr Surg Int       Date:  2008-06-05       Impact factor: 1.827

6.  Anaesthetic management of two different cases of mediastinal mass.

Authors:  Hemalatha Subbanna; Poola N Viswanathan; Manjula B Puttaswamy; Ashwini Andini; Tulsi Thimmegowda; Sondekoppa N Bhagirath
Journal:  Indian J Anaesth       Date:  2013-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.